Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.
The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug ...
Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...
The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...
Zacks.com on MSN6d
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi DrugJ&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback